Burroughs Wellcome's Navelbine
Vinorelbine NDA (20-388) will be reviewed by FDA's Oncologic Drugs Advisory Committee June 7 for the treatment of patients with metastatic breast cancer who have failed standard chemotherapy or who have relapsed within six months of anthracycline-based adjuvant therapy. The NDA was submitted March 31. The committee will also discuss the National Cancer Institute's Tamoxifen Breast Cancer Prevention Trial. The committee meeting will begin at 8:00 a.m., in conference rooms D&E of FDA's Parklawn Building
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth